Lb Pharmaceuticals Common Stock Performance
| LBRX Stock | 22.15 0.39 1.73% |
On a scale of 0 to 100, LB Pharmaceuticals holds a performance score of 12. The firm owns a Beta (Systematic Risk) of 0.35, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, LB Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding LB Pharmaceuticals is expected to be smaller as well. Please check LB Pharmaceuticals' potential upside, and the relationship between the jensen alpha and accumulation distribution , to make a quick decision on whether LB Pharmaceuticals' current price history will revert.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in LB Pharmaceuticals Common are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. In spite of fairly uncertain basic indicators, LB Pharmaceuticals showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (0.68) | Five Day Return 10.33 | Year To Date Return 27.17 | Ten Year Return 27.17 | All Time Return 27.17 |
1 | LB Pharmaceuticals to Present Three Posters at 38th ECNP Congress Highlighting Clinical Activity and Safety Profile of LB-102 in Schizophrenia, Including Positi... | 10/06/2025 |
2 | LB Pharmaceuticals Inc Given Consensus Rating of Buy by Brokerages - MarketBeat | 10/10/2025 |
3 | MapLight Therapeutics raises 258M in IPO, private placement - Axios | 10/27/2025 |
4 | LB Pharmaceuticals Inc GAAP EPS of -0.61 | 11/06/2025 |
5 | LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635 | 11/12/2025 |
6 | LB Pharmaceuticals amends lease to expand New York office space - Investing.com | 11/13/2025 |
7 | LB Pharmaceuticals Added to the Russell 2000 and Russell 3000 Indices | 12/09/2025 |
8 | Medline sets terms for 5.37bn healthcare IPO - BioXconomy | 12/12/2025 |
| Begin Period Cash Flow | 15 M | |
| Total Cashflows From Investing Activities | 23.2 M | |
| Free Cash Flow | -53.8 M |
LB Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 1,495 in LB Pharmaceuticals Common on September 25, 2025 and sell it today you would earn a total of 720.00 from holding LB Pharmaceuticals Common or generate 48.16% return on investment over 90 days. LB Pharmaceuticals Common is currently generating 0.7126% in daily expected returns and assumes 4.4981% risk (volatility on return distribution) over the 90 days horizon. In different words, 40% of stocks are less volatile than LBRX, and 86% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
LB Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for LB Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as LB Pharmaceuticals Common, and traders can use it to determine the average amount a LB Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1584
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | LBRX | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Based on monthly moving average LB Pharmaceuticals is performing at about 12% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of LB Pharmaceuticals by adding it to a well-diversified portfolio.
LB Pharmaceuticals Fundamentals Growth
LBRX Stock prices reflect investors' perceptions of the future prospects and financial health of LB Pharmaceuticals, and LB Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on LBRX Stock performance.
| EBITDA | (63.01 M) | ||||
| Net Income | (63.1 M) | ||||
| Total Debt | 3.7 M | ||||
| Cash Flow From Operations | (53.05 M) | ||||
| Total Asset | 33.53 M | ||||
| Retained Earnings | (104.32 M) | ||||
| Working Capital | 20.77 M | ||||
About LB Pharmaceuticals Performance
Evaluating LB Pharmaceuticals' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if LB Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if LB Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.88) | (1.98) | |
| Return On Capital Employed | (2.55) | (2.42) | |
| Return On Assets | (1.88) | (1.98) | |
| Return On Equity | 0.67 | 0.36 |
Things to note about LB Pharmaceuticals Common performance evaluation
Checking the ongoing alerts about LB Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for LB Pharmaceuticals Common help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| LB Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| LB Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (63.1 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| LB Pharmaceuticals generates negative cash flow from operations | |
| LB Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Medline sets terms for 5.37bn healthcare IPO - BioXconomy |
- Analyzing LB Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether LB Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining LB Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating LB Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of LB Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of LB Pharmaceuticals' stock. These opinions can provide insight into LB Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for LBRX Stock Analysis
When running LB Pharmaceuticals' price analysis, check to measure LB Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy LB Pharmaceuticals is operating at the current time. Most of LB Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of LB Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move LB Pharmaceuticals' price. Additionally, you may evaluate how the addition of LB Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.